Drug Patents owned by Daiichi Sankyo Inc

1. List of Morphabond Er drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7955619 DAIICHI SANKYO INC Abuse resistant drugs, method of use and method of making
Aug, 2028

(5 years from now)

US10314788 DAIICHI SANKYO INC Pharmaceutical compositions configured to deter dosage form splitting
Aug, 2028

(5 years from now)

Drugs and Companies using MORPHINE SULFATE ingredient

Market Authorisation Date: 02 October, 2015

Treatment: NA

Dosage: TABLET, EXTENDED RELEASE;ORAL

How can I launch a generic of MORPHABOND ER before it's patent expiration?
More Information on Dosage

2. List of Savaysa drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7365205 DAIICHI SANKYO INC Diamine derivatives
Apr, 2027

(4 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9149532 DAIICHI SANKYO INC Pharmaceutical composition
Mar, 2028

(5 years from now)

Exclusivity Exclusivity Expiration
M Aug 9, 2022

Drugs and Companies using EDOXABAN TOSYLATE ingredient

Market Authorisation Date: 08 January, 2015

Treatment: NA

Dosage: TABLET;ORAL

How can I launch a generic of SAVAYSA before it's patent expiration?
More Information on Dosage

3. List of Turalio drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9169250 DAIICHI SANKYO INC Compounds modulating c-fms and/or c-kit activity and uses therefor
Nov, 2027

(4 years from now)

US8722702 DAIICHI SANKYO INC Compounds modulating c-fms and/or c-kit activity and uses therefor
Nov, 2027

(4 years from now)

US8404700 DAIICHI SANKYO INC Compounds modulating c-fms and/or c-kit activity and uses therefor
Nov, 2027

(4 years from now)

US7893075 DAIICHI SANKYO INC Compounds modulating c-fms and/or c-kit activity and uses therefor
May, 2033

(10 years from now)

US9802932 DAIICHI SANKYO INC Solid forms of a compound modulating kinases
May, 2036

(13 years from now)

US10730876 DAIICHI SANKYO INC Synthesis of a compound that modulates kinases
May, 2036

(13 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8461169 DAIICHI SANKYO INC Compounds modulating c-fms and/or c-kit activity
Apr, 2028

(5 years from now)

US9358235 DAIICHI SANKYO INC Kinase modulation, and indications therefor
Jun, 2033

(10 years from now)

US10189833 DAIICHI SANKYO INC Solid forms of a compound modulating kinases
May, 2036

(13 years from now)

US10941142 DAIICHI SANKYO INC Formulations of a compound modulating kinases
Jul, 2038

(15 years from now)

US10961240 DAIICHI SANKYO INC Formulations of a compound modulating kinases
Jul, 2038

(15 years from now)

US10435404 DAIICHI SANKYO INC Formulations of a compound modulating kinases
Jul, 2038

(15 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Aug 2, 2024
Orphan Drug Exclusivity (ODE) Aug 2, 2026

Drugs and Companies using PEXIDARTINIB HYDROCHLORIDE ingredient

NCE-1 date: August, 2023

Market Authorisation Date: 02 August, 2019

Treatment: Treatment of adult patients with symptomatic tenosynovial giant cell tumor (tgct) associated with severe morbidity or functional limitations and not amenable to improvement with surgery

Dosage: CAPSULE;ORAL

More Information on Dosage

4. List of Welchol drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7229613 DAIICHI SANKYO INC Method for lowering serum glucose
Apr, 2022

(9 months ago)

Drugs and Companies using COLESEVELAM HYDROCHLORIDE ingredient

Market Authorisation Date: 03 April, 2019

Treatment: A method for reducing serum glucose levels in adults with type 2 diabetes mellitus

Dosage: BAR, CHEWABLE;ORAL

How can I launch a generic of WELCHOL before it's patent expiration?
More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in